REPL

Replimune Group Inc

NASDAQ: REPL · HEALTHCARE · BIOTECHNOLOGY

$5.41

+1.12% today

Updated 2026-07-29

Market cap

$858.76M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.63

Dividend yield

—

52W range

$2 – $13

Volume

5.4M

Market cap

$858.76M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.63

Dividend yield

—

52W range

$2 – $13

Volume

5.4M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-7.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$10.67

+97.23%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy1 Buy5 Hold1 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -6.95 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-56.17M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	2026	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-174.28M	$-215.79M	$-247.30M	$-313.94M	$-73.22M
EPS	—	—	—	—	$-3.63
Free cash flow	$-130.32M	$-191.13M	$-198.94M	$-284.57M	$-56.17M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-06-01	SARCHI, CHRISTOPHER	Sale	12,000	$9.24
2026-05-18	XYNOS, KONSTANTINOS	Sale	14,023	$5.08
2026-05-18	SCHWENDENMAN, ANDREW	Sale	7,894	$5.08

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
REPL	$858.76M	26	4.3	3.0	5.0	5.0	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Replimune Group Inc trades at $5.41. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -6.95, it sits in the distress.

Frequently asked questions

What is Replimune Group Inc's stock price?

Replimune Group Inc (REPL) trades at $5.41.

Is Replimune Group Inc overvalued?

Replimune Group Inc carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Replimune Group Inc (REPL)?

The 12-month analyst consensus target is $10.67, about 97.2% above the current $5.41. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Replimune Group Inc's Altman Z-Score is -6.95, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-188.94%

Beta0.87

50D MA$8.36

200D MA$7.61

Shares out0.08B

Float0.06B

Short ratio—

Avg volume5.4M

Performance

1 week-21.55%

1 month-25.80%

3 months+235.80%

YTD-11.21%

1 year—

3 years—

5 years—

Compare

REPL vs LLY →REPL vs JNJ →REPL vs ABBV →Stock screener →